secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-05-28T12:00:11+00:00
Accession:  0001437749-26-018670
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia Japan PMDA supports CardiAMP cell therapy submission for HFrEF; submission planned Q4 2026
--------------------------------------------------------------------------------

- PMDA Consultation Record confirms alignment on remaining questions; positive outcomes credible.
- Estimated 20,000 of 300,000 Japanese HFrEF patients initially eligible for CardiAMP therapy.
- BioCardia plans PMDA submission in Q4 2026 with a Designated Marketing Authorization Holder.
- Clinical data showed 179 sec average exercise tolerance improvement and 82% angina reduction.
- PMDA requested additional details on GDMT compliance, revascularization ineligibility, and adverse events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926018670/0001437749-26-018670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926018670/bcda20260528_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-018670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer